Similar articles

• A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.

  Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ 3rd, Wolka AM, Vinik AI. Casellini CM, et al. Diabetes Care. 2007 Apr;30(4):896-902. doi: 10.2337/dc06-1699. Diabetes Care. 2007. PMID: 17392551 Clinical Trial.
• Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.

  Joy SV, Scates AC, Bearelly S, Dar M, Taulien CA, Goebel JA, Cooney MJ. Joy SV, et al. Ann Pharmacother. 2005 Oct;39(10):1693-9. doi: 10.1345/aph.1E572. Epub 2005 Sep 13. Ann Pharmacother. 2005. PMID: 16160002 Review.
• Ruboxistaurin for diabetic retinopathy.

  Gardner TW, Antonetti DA. Gardner TW, et al. Ophthalmology. 2006 Dec;113(12):2135-6. doi: 10.1016/j.ophtha.2006.09.003. Ophthalmology. 2006. PMID: 17157131 No abstract available.
• Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.

  Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK. Brooks B, et al. J Diabetes Complications. 2008 Mar-Apr;22(2):88-95. doi: 10.1016/j.jdiacomp.2007.07.002. J Diabetes Complications. 2008. PMID: 18280438 Clinical Trial.
• Ruboxistaurin.

  Taulien CA, Joy SV. Taulien CA, et al. Drugs Today (Barc). 2006 Sep;42(9):577-85. doi: 10.1358/dot.2006.42.9.996566. Drugs Today (Barc). 2006. PMID: 17028667 Review.